An analysis conducted by Friends of Cancer Research showed that the FDA Breakthrough Therapy Designation criteria select drugs that lead to better outcomes for patients with lung cancer.
The study, titled “Breakthrough Therapy Designation Criteria Identify Drugs that Improve Clinical Outcomes for Patients: A Case for More Streamlined Coverage of Promising Therapies,” was published in Clinical Cancer Research.
The findings showed that FDA-approved lung cancer drugs that received BTD resulted in improved overall survival for patients when compared to lung cancer drugs that never received BTD. Additionally, the data showed that drugs with BTD are more frequently categorized as preferred treatments in clinical guidelines developed and widely used by oncologists.
Friends continues to monitor the effectiveness of BTD and has previously shown that processes enabled by BTD can compress development timelines of drugs by several years.
